API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPT 2008
(Rs. In Lacs)
Particulars Quarter ended Quarter ended Half Year Ended Half Year Ended Year ended
30th Sept 08 30th Sept 07 30th Sept 2008 30th Sept 2007 31st Mar 2008
1.
(Gross) Sales / Income from operations
10,337 8,195 20,714 15,742 33,585
2. Less : Excise Duty & Sales Tax 923 789 1,914 1,596 2,512
3.
(Net) Sales / Income from operations
9,414 7,397 18,800 14,146 31,073
4. Other Income 2 5 6 66 184
5. Total Income 9,416 7,402 18,806 14,212 31,257
Expenditure
(a)
(Increase) / Decrease in stock in trade & WIP.
(1,348) (423) (1,187) (929) (924)
(b) Consumption of raw materials. 6,953 4,610 12,131 9,216 18,259
(c) Purchase of Traded Goods 670 760 1,520 1,123 3,892
(d) Employees cost 267 230 523 468 980
(e) Depreciation 262 253 519 465 963
(f) Other expenditure 1,476 1,260 2,778 2,364 5,119
6. Total Expenditure 8,280 6,690 16,284 12,797 28,289
7. Interest 604 201 1,164 367 1,184
8. Exceptional Items - - - - -
9. Profit Before Tax (PBT) 532 512 1,359 1,1049 1,783
10. Provision for Tax 130 65 240 125 246
11. Profit After Tax (PAT) 403 446 1,118 923 1,537
12. Provision for Deferred Tax 63 43 125 100 230
13. Profit After Deferred Tax 341 403 993 823 1,307
14. Extraordinary items - - - - -
15. Net Profit for the period 341 403 993 823 1,307
16.
Paid-up Equity Share Capital of Rs.10/- each.
1,171 1,171 1,171 1,171 1,171
17.
Reserves & Surplus (excluding revaluation reserves)
- - - - -
18. Basic E P S (in Rs.) 2.91 3.45 8.48 7.03 11.17
19.
Diluted E P S (in Rs.) (FCCB Shares nett off)
2.16 2.55 6.23 5.21 8.82
20.
Aggregate of Non Promoter Shareholding
21. Number of Shares 5766044 6113030 5766044 6113030 6045866
22. Percentage of Total Shareholding 49.25 52.21 49.25 52.21 51.64

Notes :

1.There were no pending complaints at the beginning of the Quarter. During the quarter three complaintswere received and redressed. There were no complaints pending at the end of the quarter.


2.Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 'Segment Reporting' is not attracted.

3.The figures of the previous periods have been regrouped and rearranged wherever necessary.

4.The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on

For and on behalf of the Board

FOR AARTI DRUGS LIMITED

Sd/-

Place : Mumbai Harshit M Savla

Date : 30th Oct, 2009 (Jt. Managing Director)

 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech